PLAY PODCASTS
Pure Global: ASEAN's MedTech Harmonization Myth & The AMDD Reality Check

Pure Global: ASEAN's MedTech Harmonization Myth & The AMDD Reality Check

ASEAN MedTech Insights · Ran Chen

January 26, 20261m 50s

Audio is streamed directly from the publisher (episodes.captivate.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

This week, we dissect the complex reality of the ASEAN Medical Device Directive (AMDD). While the vision is a single, harmonized market, MedTech companies still face a fragmented landscape of unique national regulations, causing costly delays and complicating market access strategies across Southeast Asia. We uncover the practical differences between regulatory bodies in key markets like Singapore, Malaysia, and Vietnam, revealing why a single approval does not guarantee access to the entire region. Imagine a European MedTech company securing approval for their innovative diagnostic device in Singapore, expecting a quick rollout across ASEAN. They soon discover that their technical dossier is rejected in Malaysia for format inconsistencies and that Thailand requires additional, unforeseen in-country clinical data. This common scenario highlights the critical pain point: the myth of harmonization is costing companies millions in lost revenue and delayed patient access. Key questions from this episode: 1. Why isn't a Singapore HSA approval a golden ticket for the rest of ASEAN? 2. What are the top three undocumented differences between Malaysia's MDA and Thailand's FDA requirements? 3. How do language and local representation rules create hidden barriers to entry in Vietnam and Indonesia? 4. Is the ASEAN Common Submission Dossier Template (CSDT) actually common? 5. Which ASEAN countries are closest to true AMDD implementation, and which are lagging? 6. How can you build a regulatory strategy that anticipates these national differences? 7. What are the post-market surveillance requirements that vary most significantly between member states? Navigating these complex, fast-changing regulations is our expertise. Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, utilizing local expertise and advanced AI tools to streamline your market access. Whether you're a startup or a multinational, we turn regulatory challenges into market opportunities. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.